Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial

Br J Dermatol. 2012 Dec; 167(6):1374-81

View abstract


Strober BE, Sobell JM, Duffin KC, Bao Y, Guerin A, Yang H, Goldblum O, Okun MM, Mulani PM